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Abstract The mitogen-activated protein kinase p38 pathway
was originally identi¢ed as a signalling cascade activated by
pro-in£ammatory stimuli and cellular stresses, and playing a
critical role in the translational regulation of pro-in£ammatory
cytokine synthesis. In almost a decade since this discovery, a
great deal has been learned about the role of the p38 pathway in
the post-transcriptional regulation of pro-in£ammatory gene ex-
pression. However, important questions remain to be answered
concerning the speci¢city and mechanism or mechanisms of ac-
tion of p38. This review describes recent progress and remaining
puzzles in the ¢eld of post-transcriptional regulation by p38.
% 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. MAPK p38
The three principal mitogen-activated protein kinase
(MAPK) pathways of mammalian cells mediate changes in
cellular gene expression in response to extracellular stimuli
[1]. In many cases the extracellular signal-regulated kinase
(ERK) pathway is activated by mitogenic stimuli, whereas
the cJun N-terminal kinase (JNK) and p38 pathways are ac-
tivated by pro-in£ammatory or stressful stimuli (although
there are exceptions to this generalisation). The pathways
are organised as discrete, parallel signalling cascades in which
a MAPK kinase kinase (MKKK) phosphorylates and acti-
vates a dual-speci¢city MAPK kinase (MKK), which then
activates a MAPK by phosphorylating both threonine and
tyrosine residues in a Thr-Xxx-Tyr motif. The central amino
acid (Xxx) is a de¢ning characteristic of the particular MAPK
family, and is glutamic acid in the case of the ERKs, proline
in the case of the JNK family and glycine in the case of the
p38 family. Phosphorylation of both threonine and tyrosine
residues is essential for full MAPK activation, hence the ac-
tivity of MAPKs may be negatively regulated by members of
three phosphatase families, serine/threonine-speci¢c, tyrosine-
speci¢c or dual speci¢city. The latter family contains about 12
phosphatases, which e⁄ciently dephosphorylate both threo-
nine and tyrosine residues, and display di¡ering patterns of
expression and speci¢cities for MAPK substrates. Strength
and duration of MAPK activation determine cellular re-
sponses, and are critically regulated by the action of these
phosphatases [2]. Activated MAPKs exert their e¡ects directly
by phosphorylating substrates such as transcription factors, or
indirectly by activating downstream kinases, which in turn
phosphorylate their own substrates. At the post-transcription-
al level many of the e¡ects of MAPK p38 appear to be medi-
ated by its substrate, MAPK-activated protein kinase 2
(MAPKAPK-2; see Fig. 1).
The MAPK p38 pathway was independently discovered by
several laboratories [3]. In one study it was identi¢ed as the
target of a novel class of anti-in£ammatory drugs, which
blocked the expression of interleukin (IL-) 1 and tumour ne-
crosis factor K (TNFK) in myeloid cells stimulated with bac-
terial lipopolysaccharide (LPS) [4,5]. These novel pyridinyl
imidazole drugs inhibit p38 with sub-micromolar IC50 values
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by blocking the access of ATP to the catalytic site of the
kinase. Carefully used, they are invaluable tools for the inves-
tigation of p38 function, although at higher concentrations
the inhibition of other kinase pathways may become signi¢-
cant. To date four members of the p38 MAPK family have
been cloned: p38-K, -L, -Q and -N. The Q and N isoforms are
insensitive to the pyridinyl imidazole inhibitors, for which
reason their function has been di⁄cult to explore. This review
concentrates on MAPKs p38-K and -L, which appear similar
in function, and are intimately linked to both in£ammation
and post-transcriptional regulation.
2. Post-transcriptional regulation of gene expression
Mechanisms of post-transcriptional regulation of gene ex-
pression are very well reviewed elsewhere [6^8] and will be
described here only in outline. Eukaryotic mRNA is modi¢ed
at the 5P end by addition of a methyl guanosine cap, and at
the 3P end by addition of a poly-(A) tail. The poly-(A) tail is
recognised by the highly abundant cytoplasmic poly-(A)-bind-
ing protein 1 (PABPc1), and the 5P cap is bound by eukaryotic
initiation factor 4F (eIF4F), a high molecular-weight complex
consisting of eIF4E (the direct cap-binding component),
eIF4G and eIF4A. Direct or indirect interactions between
cap-binding and poly-(A)-binding factors e¡ectively circular-
ise the mRNA, increasing its stability and e⁄ciency of trans-
lation [9]. Degradation of mRNA is in£uenced by both 5P cap
and 3P poly-(A) tail, and by sequences within the 5P untrans-
lated region (UTR), 3P UTR or coding sequence. Recently,
most attention has been given to the regulation of mRNA
decay by adenosine- and uridine-rich elements (AREs), lo-
cated within the 3P UTRs of unstable mRNAs and generally
containing a number of copies of the pentamer sequence
AUUUA [10,11]. According to the classi¢cation proposed
by Shyu and his colleagues, class I AREs contain dispersed
pentamers within a uridine-rich context, whereas class II
AREs contain clustered, often overlapping copies of the pen-
tamer, and class III AREs do not possess canonical AUUUA
motifs [12]. AREs are thought to control mRNA degradation
via interactions with speci¢c binding proteins (AREBPs). Sev-
eral such proteins have been identi¢ed, although only a few
have been clearly implicated in the regulation of mRNA
stability. HuR is believed to stabilise transcripts to which it
binds, whereas mRNA destabilisation is a property of the zinc
¢nger RNA binding proteins tristetraprolin (TTP) and buty-
rate response factor 1 (BRF-1), as well as the ARE/poly-(U)-
binding/degradation factor (AUF1) [6^8,13].
Degradation of mRNA may be initiated by endonucleolytic
cleavage within AREs or by removal of the 5P cap and exo-
nucleolytic digestion in the 5P to 3P direction [14,15]. However,
3P to 5P exonucleolytic digestion is believed to be the major
pathway for degradation of mammalian mRNAs. The poly-
(A) tail protects against 3P to 5P degradation, therefore poly-
(A) removal is thought to be an obligate ¢rst step in mRNA
decay. Both deadenylation and 3P to 5P decay of the mRNA
body are stimulated by AREs in vitro or in vivo [12,16^21].
The control of 3P to 5P degradation involves the recruitment
by AREBPs of a multi-component exonucleolytic complex,
the exosome [17,21]. The regulation of deadenylation is less
well understood; however, some AREBPs have been shown to
interact with PABPc1, or directly with the poly-(A) tail itself,
which may mediate crosstalk between the ARE and the reg-
ulation of poly-(A) tail length [22^24]. The processes of trans-
lation and mRNA degradation are closely coupled, and may
be regulated by common ARE-dependent mechanisms, as dis-
cussed below.
3. MAPK p38 and the post-transcriptional regulation of
pro-in£ammatory gene expression
In early experiments the blockade of TNFK and IL-1L pro-
tein synthesis by p38 inhibitors was accompanied by little or
no change in the corresponding steady-state mRNA levels,
suggesting that p38 activity is essential for translation of these
transcripts [25,26]. Consistent with this hypothesis, ribosomal
density-gradient pro¢ling showed that TNFK mRNA was
Fig. 1. The MAPK p38 pathway. Some aspects of the MAPK p38 signal transduction pathway are illustrated schematically. Upstream (mem-
brane proximal) signalling events, several kinases and substrates including transcription factors are omitted for the sake of clarity. Adapted
from [1].
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mainly found in monosomal rather than actively translated
polysomal fractions in the presence of a p38 inhibitor
[26,27]. Furthermore, a mouse knockout of MAPKAPK-2
resulted in impairment of TNFK protein synthesis, with no
discernible change in TNFK mRNA steady-state levels or
stability [28,29]. Another informative mouse strain carries a
targeted genomic deletion of a conserved ARE in the TNFK
3P UTR [30]. This deletion caused overproduction of TNFK
and loss of sensitivity to the p38 inhibitors. Hence p38 is
thought to act through its substrate MAPKAPK-2 to release
TNFK mRNA from a state of translational arrest imposed by
the ARE. ARE-mediated translational arrest of TNFK bio-
synthesis is also a feature of LPS tolerance, a state in which
myeloid cells pretreated with low doses of LPS are refractory
to further stimulation with this agonist [31,32]. Glucocorti-
coids (GCs) may similarly inhibit the expression of TNFK
protein but not mRNA [33,34]. Both of these phenomena
are likely to involve suppression of p38 activity. The basis
of the inhibition of translation and the mechanism of dere-
pression are not known. T-cell-restricted intracellular antigen
1 (TIA-1) and T-cell-restricted intracellular antigen-related
protein (TIAR) have been identi¢ed as TNFK 3P UTR-bind-
ing translational silencers, but do not appear to be targets of
the p38 pathway [27].
A role for MAPK p38 in the control of pro-in£ammatory
mRNA translation initially seemed clear, and was borne out
by other studies [35]. However, p38 inhibitors blocked the
expression of another pro-in£ammatory mediator, cyclooxy-
genase 2 (COX-2), at both protein and steady-state mRNA
levels, suggesting a function other than translational regula-
tion [36]. In IL-1-stimulated HeLa cells [37] or LPS-stimulated
primary human monocytes [38] a p38 inhibitor profoundly
destabilised COX-2 mRNA. Regulation of COX-2 mRNA
stability by the p38 pathway has also been demonstrated in
several other cell systems (see Fig. 2). Similarly, in primary
human monocytes the expression of TNFK was blocked at
both protein and mRNA levels by a p38 inhibitor [38]. The
blockade of TNFK expression by p38 inhibitors was shown to
involve mRNA destabilisation in primary human monocytes
[39], a human monocytic cell line [40] and a mouse macro-
phage-like cell line [41]. Many other pro-in£ammatory medi-
ators are regulated by p38 at the level of mRNA stability
(references in Fig. 2). One target of the MAPK p38 pathway
was identi¢ed as IL-6 mRNA, which showed markedly de-
creased stability in macrophages from the MAPKAPK-2
knockout mouse [42], and was destabilised by a p38 inhibitor
in human synoviocytes [43]. Reporter assays and other experi-
ments con¢rmed that stabilisation of COX-2, IL-6, IL-8 and
TNFK mRNAs was mediated by MAPKAPK-2, and was de-
pendent upon ARE sequences [41,42,44^46]. Hence the p38
pathway may regulate either translation or mRNA stability in
a single cell type, and a particular mRNA may be regulated at
either of these two post-transcriptional levels, depending upon
cell type or species. Furthermore, both phenomena are MAP-
KAPK-2-mediated and dependent upon AREs. The close cou-
pling of translation and mRNA stability [47] suggests that
Fig. 2. Post-transcriptional targets of MAPK p38, GCs and IL-10 [29,33-35,37-46,52,54,56,67,69,73-75,84,87-111]. The 3P UTRs of several p38-
sensitive, GC-sensitive and/or IL-10-sensitive mRNAs are illustrated to scale, and the positions of AUUUA motifs indicated. Selected mRNAs
from [50] are included, namely those which were both induced by LPS treatment of THP-1 cells and destabilised by a p38 inhibitor. Several of
the observations from that study have not yet been con¢rmed by Northern blotting or reverse-transcription polymerase chain reaction.
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these two facets of post-transcriptional regulation by p38
share a common mechanistic core (see below and [48]).
In vitro di¡erentiation of primary human monocytes has
been shown to alter the stability of TNFK mRNA and the
kinetics of its accumulation [49]. This di¡erentiation is mim-
icked by treatment of the human monocytic cell line THP-1
with PMA (phorbol-12-myristate-13-acetate). In di¡erentiated
THP-1 cells TNFK mRNA stability was sensitive to p38 inhi-
bition [40] whereas in undi¡erentiated cells it was not [50],
hence p38 sensitivity may be a developmentally acquired state.
Other inconsistencies in the control of mRNA stability by p38
have been noted. For example, the stability of the chemokine
CXCL3 mRNA was sensitive to p38 inhibitors in THP-1 cells
[50] but not in the myeloid T98G glioblastoma cell line [51],
whereas the reverse was true of granulocyte/macrophage col-
ony stimulating factor (GM-CSF) mRNA. E¡ects on protein
synthesis were not reported; for example, it is not known
whether CXCL3 expression in T98G or GM-CSF expression
in THP-1 cells is translationally regulated by p38. Neverthe-
less, these inconsistencies may provide clues to the mecha-
nisms of post-transcriptional regulation by the MAPK p38
pathway. In T98G glioblastoma cells p38-dependent stabilisa-
tion of GM-CSF mRNA was not apparent until 2 h after
stimulation with LPS, and was dependent upon ongoing pro-
tein synthesis [51]. At least two interpretations are possible:
¢rstly, that sensitivity to p38 requires the synthesis of a regu-
latory protein, which is expressed in response to the activating
stimulus; secondly, that sensitivity to p38 requires the target
mRNA to be in a translationally active compartment (see also
[52]). Again, further analysis of this system may provide in-
sights into mechanisms of regulation by p38.
In LPS-stimulated RAW264.7 cells [41] or in IL-1-stimu-
lated HeLa cells [53] a strong, rapid activation of p38 was
followed by a sustained phase of lower, yet signi¢cant activity.
Inhibition of p38 during this sustained second phase destabi-
lised TNFK [41] or COX-2 [37] mRNA, and profoundly in-
hibited the expression of COX-2 protein [53]. This suggests
that a quantitatively modest though sustained activation of
p38 may be essential for the maintenance of mRNA stability
and e⁄cient expression of certain pro-in£ammatory genes.
Although the pro-in£ammatory cytokines IL-1 and TNFK
are generally similar in their abilities to activate signal trans-
duction pathways, di¡erential regulation of mRNA stability
by these two agonists has been described [51,54,55]. In micro-
vascular endothelial cells the di¡erential induction of COX-2
mRNA by IL-1 and TNFK was explained by the ability of
IL-1 but not TNFK to cause p38 activation and COX-2
mRNA stabilisation [54]. Other possible explanations of dif-
ferential regulation of mRNA stability by IL-1 and TNFK
include dissimilar kinetics of p38 activation (particularly in
the sustained phase) [51] or di¡erent abilities to induce the
expression of regulatory proteins. These possibilities remain
to be explored.
The stability of MKK6 mRNA (encoding an upstream ac-
tivator of p38) was positively regulated by p38 in THP-1 cells
[50], suggesting a positive feedback loop which may modulate
p38 signalling. Curiously, p38 appeared to destabilise MKK6
mRNA in mouse cardiac myocytes and human HEK293 cells,
suggesting a negative feedback loop [56]. To our knowledge
this is the ¢rst description of p38-dependent mRNA destabi-
lisation, and it will be interesting to determine whether this is
also MAPKAPK-2 dependent and ARE-mediated.
4. MAPK p38 as a target of anti-in£ammatory agonists
MAPK p38 is strongly activated by pro-in£ammatory stim-
uli, and has been studied largely in the context of in£amma-
tion [3,57]. Very many mRNAs stabilised by p38 encode in-
£ammatory mediators or other immunomodulators (Fig. 2),
suggesting that this kinase pathway plays a major role in the
regulation of the in£ammatory response. If the regulation of
mRNA translation or stability by the p38 pathway plays a
physiologically signi¢cant role in the expression of pro-in£am-
matory genes it follows that inhibition of this pathway may be
a versatile anti-in£ammatory strategy. This accounts for the
intense interest of the pharmaceutical industry in the develop-
ment of p38 or MAPKAPK-2 inhibitors [58].
It has recently been shown that GCs, which are powerful
anti-in£ammatory agents, induce rapid and prolonged expres-
sion of MAPK phosphatase 1 (MKP-1) [53,59^62], a dual-
speci¢city phosphatase which potently inactivates p38 [63].
In the macrophage cell line RAW264.7 the expression of
MKP-1 was associated with decreased expression of IL-6
and TNFK [60], which are known post-transcriptional targets
of the p38 pathway. In HeLa cells the induction of MKP-1
and inhibition of p38 by GCs resulted in the destabilisation of
a reporter mRNA containing a COX-2 ARE [53]. Further-
more, GCs destabilised COX-2 mRNA even when added to
cells long after the activating stimulus [53,73], presumably by
targeting the sustained phase of p38 activity. This late e¡ect
may be relevant to the role of GCs in the resolution of in-
£ammation. Many pro-in£ammatory genes are post-transcrip-
tionally repressed by GCs, possibly by means of the same
mechanism (Fig. 2). Interestingly, the expression of MKP-1
is induced by other anti-in£ammatory agonists such as trans-
forming growth factor L (TGFL) [64], the B subunit of cholera
toxin [60] and cAMP elevating agents [65,66].
The potent anti-in£ammatory cytokine IL-10 also destabi-
lised a number of ARE-containing transcripts (see Fig. 2).
The destabilisation of KC mRNA (encoding a mouse
CXCL2 homologue) was dependent upon an ARE within its
3P UTR [67,68]. The inhibition of TNFK biosynthesis was
similarly mediated by its 3P UTR [69]. Like p38 inhibitors,
IL-10 inhibited the translation of TNFK in primary mouse
macrophages, and this translational blockade was impaired
in mice which expressed an internally deleted TNFK
mRNA, lacking the ARE [29]. The IL-10-dependent inhibi-
tion of TNFK biosynthesis was impaired in mouse macro-
phages lacking MAPKAPK-2 [29]. These observations are
consistent with post-transcriptional inhibition of gene expres-
sion through the inhibition of p38 function by IL-10. How-
ever, such an e¡ect remains controversial, having been ob-
served by some groups [29,70,71] but not by others [69,72].
5. Mechanism, speci¢city and functional targets of the MAPK
p38 pathway
As illustrated in Fig. 3, the p38 pathway could post-tran-
scriptionally regulate gene expression at any of several stages.
Regulation at the level of polyadenylation and/or the interac-
tions between 5P and 3P termini could account for the e¡ects
of p38 upon both translation and mRNA stability. In RAW-
264.7 cells destabilisation of TNFK mRNA by SB203580
was preceded by apparent shortening of the transcript [41] ;
however, it has not been demonstrated that this corresponds
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to deadenylation. In A594 cells destabilisation of COX-2
mRNA by the synthetic GC dexamethasone was deadenyla-
tion-mediated [73]. Although dexamethasone induces MKP-1
expression in A549 cells (R. Newton, personal communica-
tion), a causal link between p38 inhibition and deadenylation
has not been proven. In conclusion, circumstantial evidence
suggests a role for p38 in the regulation of the poly-(A)
tail length; however, all of the theoretical mechanisms illus-
trated in Fig. 3 remain possible, and are not mutually exclu-
sive.
Transcript-speci¢c regulation of mRNA stability or trans-
lation is presumably critical to the biological e¡ects of the p38
pathway, yet is poorly understood. For example, many proto-
oncogene mRNAs are unstable and contain AREs, but are
not responsive to the p38 pathway [40,45,50,51]. Speci¢city
cannot be explained simply in terms of AUUUA pentamers,
although these are clearly involved in responses to p38. A
GM-CSF ARE consisting of ¢ve overlapping pentamers con-
ferred neither instability nor p38-mediated stabilisation, but
required £anking sequences to function as a p38-responsive
instability determinant [41,44]. A 76 nucleotide p38 responsive
region of the COX-2 3P UTR contains two discrete clusters of
three pentamers. Mutation of pentamer motifs within either
cluster resulted in loss of destabilising function, consequently
stabilisation in response to p38 could not be measured. The
shortest sequence element we have found to confer p38-medi-
ated mRNA stabilisation was a 44 nucleotide TNFK ARE,
containing six pentamers in 1-2-3 con¢guration (i.e. single,
two overlapping, three overlapping) [41]. These observations
suggest that p38-regulated mRNA decay may be associated
with a complex arrangement of several pentamer motifs.
However, matrix metalloproteinase (MMP-) 3 [74] and several
other p38 targets identi¢ed by a microarray-based analysis of
global mRNA decay rates [50] possess only one 3P AUUUA
motif (Fig. 2). The latter study could ¢nd no clear correlation
of p38 sensitivity with the presence of a particular class of
ARE (I or II). To understand speci¢city it may be necessary
to consider the contexts of RNA sequence or secondary struc-
ture in which AUUUA motifs are found.
We have performed a detailed mutational analysis of a
single short p38-responsive element of the COX-2 3P UTR
and correlated changes in function with changes in the bind-
ing of AREBPs (Dean et al., in preparation). Mutations which
resulted in loss of HuR binding in vitro, but did not alter the
binding of AUF-1 and other AREBPs, caused the stabilisa-
tion of a reporter mRNA. The p38-responsiveness of the sta-
ble mutant transcript could, of course, not be investigated.
Another study implicated HuR as a functional target of the
p38 pathway [75]. A reporter mRNA containing the IL-3
3PUTR was destabilised by coexpression of TTP. This e¡ect
was counteracted by coexpression of HuR and constitutively
active MKK6, but not by expression of either of these alone.
On the other hand, the expression of either HuR or MKK6
alone was capable of stabilising reporter mRNAs in the ab-
sence of TTP, implying p38-independent actions of HuR
[75,76]. Several of the post-transcriptional targets of the p38
pathway are known to bind to HuR [7] ; however, this could
simply re£ect the important role of HuR in the post-transcrip-
tional metabolism of unstable mRNAs rather than a direct
involvement in p38-mediated regulation.
Knockout mouse, reporter gene and other experiments sug-
gest that major post-transcriptional e¡ects of the MAPK p38
pathway are likely to be mediated by MAPKAPK-2 [28,
42,44^46]. For this reason several labs have attempted to
identify regulators of mRNA stability which are phosphory-
lated by MAPKAPK-2. Phosphomimetic mutants of the small
(27 kDa) heat shock protein hsp27, the best-known substrate
of MAPKAPK-2, stabilised a L-globin-COX-2 reporter
mRNA [45]; however, the speci¢city of this e¡ect is not yet
clear. Under some conditions hsp27 was found in stress gran-
ules, which also contained polyadenylated mRNAs, PABPc1
and the translational inhibitors TIA-1 and TIAR [77]. How-
ever, the formation of these translationally inert granules ap-
pears to be a response to extraphysiological stress, and may
not be related to the normal regulation of pro-in£ammatory
gene expression.
One study suggested that TTP may be phosphorylated by
MAPKAPK-2 [78], whereas others pointed to phosphoryla-
tion of TTP by MAPK p38 itself [79,80]. It has not yet been
demonstrated that either kinase phosphorylates TTP in vivo,
therefore the physiological relevance of these observations is
uncertain. However, it is clear that TTP is not required for the
stabilisation of mRNAs by the p38 pathway, as HeLa cells are
capable of p38-mediated mRNA stabilisation but do not ex-
press TTP (our unpublished observations). The phenotype of
the TTP knockout suggests a myeloid- or lymphoid-speci¢c
role in the regulation of the o¡-phase of cytokine synthesis
[29,81^83]. Finally, the expression of TTP in RAW264.7 cells
was blocked by a p38 inhibitor [78], therefore MAPK p38
may regulate both on and o¡ phases of TNFK synthesis by
distinct mechanisms.
Two recent publications describe a⁄nity puri¢cation meth-
ods to identify MAPKAPK-2 substrates which interact with
ARE-containing mRNAs. This and the EMSA (electrophoret-
ic mobility shift assay) method may detect distinct ARE^
AREBP interactions since they di¡er greatly in terms of pro-
tein concentration, quantity of RNA substrate and other pa-
Fig. 3. Hypothetical mechanisms of post-transcriptional regulation
by MAPK p38. This ¢gure illustrates post-transcriptional events or
processes which might be regulated by p38. This is not an exhaus-
tive list, nor is it implied that di¡erent mechanisms are mutually ex-
clusive. 1, Export of mRNA from the nucleus to the cytoplasm, or
to particular sites of translation in the cytoplasm. 2, mRNA transla-
tion (or initiation). 3, Binding of AREBPs to AREs. 4, Interaction
of other RNA binding proteins with AREBPs and/or directly with
RNA. 5, Interaction of AREBPs with cap binding or poly-(A)-bind-
ing factors. 6, Interactions between cap binding and poly-(A)-bind-
ing factors. 7, Recruitment or activity of deadenylating complexes.
8, Recruitment or activity of the exosome. 9, Recruitment or activ-
ity of 5P decapping and/or 5P to 3P degradation machinery.
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rameters. In one study [84], TNFK ARE-binding proteins
were a⁄nity puri¢ed from RAW264.7 cells and incubated in
vitro with recombinant MAPKAPK-2. Of the many proteins
bound to the a⁄nity column only hnRNPA0 and a second
protein tentatively identi¢ed as RBM7 (RNA-binding motif 7
protein) were phosphorylated. In vitro, recombinant GST-
hnRNPA0 was phosphorylated by MAPKAPK-2 at serine
84, which lies within a consensus phosphorylation sequence.
Phosphorylation of the same residue in vivo was stimulated by
LPS, and dependent upon the MAPK p38 pathway. Finally,
ARE-containing mRNAs COX-2, TNFK and CXCL2 (other-
wise known as GRO2 (growth related oncogene 2) or MIP2
(macrophage in£ammatory protein 2)) co-immunoprecipitated
with hnRNPA0 in a p38-dependent manner. HnRNPA0 was
originally cloned by a⁄nity puri¢cation with an ARE sub-
strate, but did not correspond to a high-a⁄nity ARE-binding
protein which was sought in that study and later identi¢ed as
HuR [85]. Further studies are required to determine the pre-
cise binding speci¢city of hnRNPA0 and its role in the post-
transcriptional regulation of gene expression by MAPK p38.
In a similar approach, GM-CSF ARE-binding proteins
were a⁄nity-puri¢ed using a biotinylated RNA, then analysed
by mass spectrometry [86]. This study also identi¢ed
hnRNPA0 as an ARE-binding protein; however, the ARE-
binding protein most strongly phosphorylated by recombinant
MAPKAPK-2 was PABPc1. PABPc1 is an extremely abun-
dant cytoplasmic protein, which could bind non-speci¢cally
under conditions of high RNA and protein concentrations.
However, it did not bind to a control RNA lacking an
ARE, and its interaction with the GM-CSF AREs was resis-
tant to high salt concentrations, suggesting high a⁄nity. It
will be interesting to learn whether PABPc1 interacts with
other p38-sensitive AREs, whether such interactions are direct
or indirect, whether MAPKAPK-2-mediated phosphorylation
of PABPc1 occurs in vivo, and if so, what fraction of the
cellular pool is modi¢ed. In theory the phosphorylation of
PABPc1 by MAPKAPK-2 could mediate changes in poly-
(A) tail length and/or the higher order structure of an
mRNA. However, the intriguing question is how selective
post-transcriptional regulation could be achieved, since
PABPc1 binds unselectively to all polyadenylated mRNAs.
One possibility is that a secondary interaction of PABPc1
with AREs or AREBPs mediates selectivity. Another is that
MAPKAPK-2 is speci¢cally recruited to certain mRNAs, for
example through interaction with ARE-binding proteins, and
then mediates transcript-speci¢c phosphorylation of PABPc1.
This would be analogous to mechanisms of transcriptional
regulation, in which transcription factors recruit chromatin
modifying enzymes in a sequence-speci¢c and/or activation-
speci¢c manner to bring about promoter-targeted modi¢ca-
tions of histone proteins, which themselves possess no pro-
moter speci¢city.
6. Summary
A major function of the MAPK p38 pathway is the regu-
lation of pro-in£ammatory gene expression, although micro-
array-based analyses of mRNA turnover suggest additional
targets. The maintenance of stability or translatability of
pro-in£ammatory mRNAs appears to require sustained, albeit
quantitatively modest p38 activity. Anti-in£ammatory ago-
nists may exert their e¡ects partly by targetting this sustained
phase of p38 activity, bringing about a rapid and speci¢c post-
transcriptional shutdown of gene expression. Post-transcrip-
tional e¡ects of the p38 pathway are mediated by the kinase
MAPKAPK-2 and by AREs within the 3P UTRs of certain
mRNAs. Beyond this, the mechanism of action of p38 is not
well understood. Although a number of AREBPs have been
shown to be phosphorylated by MAPKAPK-2, much further
work is required to establish the role of these phosphoryla-
tions in post-transcriptional regulation. A related challenge is
to understand the basis of transcript-selective regulation by
the p38 pathway, since target mRNAs are extremely diverse
in the sequence and structure of their 3P UTRs. A more de-
tailed understanding of these processes may result in the de-
velopment of novel methods of intervention in in£ammatory
processes.
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